National Pharmaceuticals Completes Licensing of GLB333 From Globe Labs
Tuesday March 22, 2011, 4:00 pm EDT
MIAMI, FLORIDA--(Marketwire - 03/22/11) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM - News) or the "Company" announced today that it has completed the licensing of GLB333 from Globe Laboratories. NFRM obtained the worldwide exclusive license to the use and marketing of a cytokine that is shown to have profound effects on the management of pain due to trauma, wound, and accidents, as well as autoimmune conditions. The product under the internal name GLB333 has a different mechanism of action to current pain killers or analgesics. It helps to rebuild the damage tissues, reduces inflammatory conditions and help to regenerate good and healthy muscle and soft tissues. Globe Laboratories has worked on the biology and use of the product for several years and has spent considerable resources on its development. The license is for twenty years and carries standard terms and conditions used by other companies in this sector.
"We are pleased to obtain the exclusive license to the technology on worldwide basis for GLB333. The product that has considerable data already, will be ready for clinical trials Phase I/II in near future," said Elaine Affleck, President of National Pharmaceuticals Corp.
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM